Corporate Investments In Biotech
This article was originally published in Start Up
Public biotechs now rely as much as ever on institutional funding, as public equity markets remain chilly. But, for a step-up in valuation, biotechs can only turn to corporate investors, who might be persuaded to pay a strategic premium.
You may also be interested in...
As the public market for biotech issues has dried up, it's not surprising that public biotechs would rely more heavily on institutional investors for financing. Notable, however, is that so far this year, publicly traded biotechs have actually raised more cash privately than they have in follow-on public offerings.
While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.
While the venture capital community spent roughly the same in biopharma investments in 2006 as they did in 2005, they put considerably more money into mid-stage companies (Series B and C investments), and slightly less into Series A and mezzanine rounds, than they had in 2005.